Parsec Financial Management Inc. raised its position in shares of Eli Lilly and Company (NYSE:LLY) by 18.9% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 52,705 shares of the company’s stock after buying an additional 8,395 shares during the quarter. Parsec Financial Management Inc.’s holdings in Eli Lilly and were worth $4,338,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of the business. Vanguard Group Inc. lifted its position in shares of Eli Lilly and by 3.3% in the first quarter. Vanguard Group Inc. now owns 68,597,006 shares of the company’s stock worth $5,769,694,000 after purchasing an additional 2,181,701 shares in the last quarter. BlackRock Inc. lifted its position in shares of Eli Lilly and by 2,628.5% in the first quarter. BlackRock Inc. now owns 62,260,488 shares of the company’s stock worth $5,236,731,000 after purchasing an additional 59,978,664 shares in the last quarter. State Street Corp lifted its position in shares of Eli Lilly and by 1.6% in the first quarter. State Street Corp now owns 42,363,935 shares of the company’s stock worth $3,563,230,000 after purchasing an additional 651,424 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Eli Lilly and by 8.4% in the first quarter. Geode Capital Management LLC now owns 9,103,975 shares of the company’s stock worth $764,597,000 after purchasing an additional 708,597 shares in the last quarter. Finally, Janus Capital Management LLC lifted its position in shares of Eli Lilly and by 2.8% in the first quarter. Janus Capital Management LLC now owns 8,723,692 shares of the company’s stock worth $733,731,000 after purchasing an additional 237,619 shares in the last quarter. 75.72% of the stock is owned by institutional investors.

In related news, major shareholder Lilly Endowment Inc sold 180,000 shares of the company’s stock in a transaction on Thursday, August 31st. The stock was sold at an average price of $81.06, for a total transaction of $14,590,800.00. Following the completion of the sale, the insider now directly owns 123,865,804 shares in the company, valued at approximately $10,040,562,072.24. The sale was disclosed in a filing with the SEC, which is available through this link. Over the last 90 days, insiders have sold 590,000 shares of company stock valued at $48,551,300. 0.20% of the stock is owned by corporate insiders.

Several brokerages recently weighed in on LLY. Jefferies Group LLC reaffirmed a “buy” rating and set a $89.00 price objective on shares of Eli Lilly and in a research report on Monday, September 11th. BMO Capital Markets reaffirmed an “underperform” rating and set a $71.00 price objective (down previously from $73.00) on shares of Eli Lilly and in a research report on Wednesday, September 6th. Piper Jaffray Companies reaffirmed an “overweight” rating and set a $105.00 price objective (up previously from $103.00) on shares of Eli Lilly and in a research report on Friday, September 8th. Zacks Investment Research raised shares of Eli Lilly and from a “hold” rating to a “buy” rating and set a $94.00 price objective on the stock in a research report on Monday, July 17th. Finally, Oppenheimer Holdings, Inc. lowered shares of Eli Lilly and from an “outperform” rating to a “market perform” rating and set a $90.00 price objective on the stock. in a research report on Wednesday, July 26th. Three investment analysts have rated the stock with a sell rating, seven have issued a hold rating and twelve have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $88.27.

ILLEGAL ACTIVITY NOTICE: “Parsec Financial Management Inc. Has $4.34 Million Holdings in Eli Lilly and Company (LLY)” was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this story on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark law. The correct version of this story can be read at https://www.thecerbatgem.com/2017/09/28/parsec-financial-management-inc-has-4-34-million-holdings-in-eli-lilly-and-company-lly.html.

Eli Lilly and Company (NYSE LLY) opened at 84.65 on Thursday. The company has a market capitalization of $89.31 billion, a PE ratio of 36.63 and a beta of 0.34. The firm’s 50 day moving average price is $80.84 and its 200-day moving average price is $82.02. Eli Lilly and Company has a one year low of $64.18 and a one year high of $86.72.

Eli Lilly and (NYSE:LLY) last released its earnings results on Tuesday, July 25th. The company reported $1.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.05 by $0.06. The company had revenue of $5.82 billion for the quarter, compared to analyst estimates of $5.60 billion. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. Eli Lilly and’s quarterly revenue was up 7.8% on a year-over-year basis. During the same period in the prior year, the firm posted $0.86 EPS. Equities analysts forecast that Eli Lilly and Company will post $4.16 earnings per share for the current fiscal year.

Eli Lilly and Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Stock Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related stocks with our FREE daily email newsletter.